Ionis Pharmaceuticals' TRYNGOLZA (olezarsen) Becomes First FDA-Approved Treatment For Adults with Familial Chylomicronemia Syndrome
IONSDecember 20, 2024
Read more →Trading Halt: Halt status updated at 6:55:00 PM ET: Quotation Resumption: News and Resumption Times
IONSDecember 19, 2024
Read more →Trading Halt: Halted at 4:28:30 p.m. ET - Trading Halt: Halt News Pending
IONSDecember 19, 2024
Read more →Piper Sandler Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $62
IONSNovember 14, 2024
Read more →Ionis Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results and announced the pivotal Phase 3 study design following alignment with the FDA on ION582 for Angelman syndrome.
IONSNovember 6, 2024
Read more →Ionis Pharmaceuticals Q3 2024 Adj EPS $(0.72) Beats $(1.16) Estimate, Sales $134.00M Beat $130.13M Estimate
IONSNovember 6, 2024
Read more →Ionis Pharmaceuticals Announced The Pivotal Phase 3 Study Design Following Alignment With The FDA On ION582 For Angelman Syndrome
IONSNovember 6, 2024
Read more →Ionis Announces FDA Acceptance Of New Drug Application For Donidalorsen, Aiming For First-In-Class RNA-Targeted Treatment For Hereditary Angioedema; PDUFA Date Set For August 21, 2025
IONSNovember 4, 2024
Read more →Ionis Pharmaceuticals Announced Topline Data From HALOS Phase 1/2A Open-label Study Of ION582 In Angelman Syndrome, ION582 Was Safe And Well Tolerated In The Study And Showed Encouraging And Consistent Benefits
IONSMay 16, 2024
Read more →There's 'Outsized' Risk-Reward For This Biotech, Morgan Stanley Says, Predicting Shares Could Grow More Than 30%
IONSSeptember 9, 2022
Read more →Analyst Ratings for Ionis Pharmaceuticals
IONSOver the past 3 months, 6 analysts have published their opinion on Ionis Pharmaceuticals (NASDAQ:IONS) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
September 9, 2022
Read more →Morgan Stanley Upgrades Ionis Pharmaceuticals to Overweight, Raises Price Target to $57
IONSSeptember 9, 2022
Read more →Recap: Ionis Pharmaceuticals Q1 Earnings
IONSIonis Pharmaceuticals (NASDAQ:IONS) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
May 4, 2022
Read more →UPDATE: Ionis Pharmaceuticals Q1 Adj. EPS $(0.27)
IONSMay 4, 2022
Read more →Ionis Pharmaceuticals Q1 Adj. EPS $(0.27) Beats $(0.71) Estimate, Sales $142.00M Beat $125.21M Estimate
IONSMay 4, 2022
Read more →